ALLEGAN, Mich., April 13, 2011 /PRNewswire/ -- Perrigo (Nasdaq: PRGO;TASE) today announced that its partner, Teva Pharmaceutical Industries, Ltd. (Nasdaq: TEVA), has received final OTC approval to ...

Sept. 10, 2003 — Fexofenadine and cetirizine are equally effective in seasonal allergic rhinitis (SAR) but fexofenadine is less sedating, according to the results of a randomized, double-blind trial ...

— Perrigo Co. says it has acquired exclusive rights to sell over-the-counter, store-brand versions of Sanofi-Aventis’ seasonal allergy products Allegra and Allegra D-12. Sanofi-Aventis has applied to ...

Allegan-based Perrigo Co. (Nasdaq: PRGO) Tuesday announced that it has acquired the exclusive United States store brand rights to sell and distribute over-the-counter versions of Fexofenadine HCl 180 ...

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of ...

Dr Reddy’s Laboratories Ltd., an integrated pharmaceutical company, announced the first-to-market launch of the US Food and Drug Administration (FDA) approved over-the-counter (OTC) fexofenadine HCl ...

Sanofi-Aventis has applied to the FDA for the Rx-to-OTC switch of these drugs. Prior to generic competition entering the Fexofenadine Rx market in 2005, Allegra 180 mg and 60 mg had combined annual ...

Dr. Reddy’s is offering the first to market over-the-counter fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg extended-release tablets, a store-brand equivalent of Aventis’s Allegra-D 24 HR.

Allegra-D and Allegra Hives are over-the-counter (OTC) medications used to treat allergy symptoms. Both drugs belong to a drug class called antihistamines. Although Allegra-D and Allegra Hives treat ...